Del-desiran Therapy for Myotonic Dystrophy Type 1
This paper details the results of a Phase 1-2 clinical trial investigating a new treatment for myotonic dystrophy type 1, a progressive and currently incurable neuromuscular disease. The study tested ...
4 Mar 16min
Long-Term Efficacy and Safety of Tofersen in SOD1-ALS Patients
This paper details the final long-term results of the VALOR study and its open-label extension, which investigated the efficacy of tofersen in adults with SOD1-ALS. Researchers compared patients who b...
3 Mar 12min
Movement Disorders and Oculomotor Abnormalities in Whipple's Disease
This systematic review explores the neurological manifestations of Whipple’s disease, a rare infection caused by the bacterium Tropheryma whipplei. The authors analyzed 168 cases to identify key movem...
2 Mar 18min
Acute Disseminated Encephalomyelitis (ADEM): Review
This review examines acute disseminated encephalomyelitis (ADEM), a rare immune-mediated disorder characterized by widespread inflammation and demyelination in the central nervous system. Primarily af...
1 Mar 14min
A refresher on abnormal spontaneous EMG activities
This medical text details the evaluation of abnormal spontaneous electromyographic (EMG) activity, which serves as a vital diagnostic indicator for various neuromuscular disorders. While healthy skele...
27 Feb 20min
A Review of Posterior Reversible Encephalopathy Syndrome (PRES)
The provided source is a comprehensive narrative review of Posterior Reversible Encephalopathy Syndrome (PRES), an acute neurological condition defined by brain edema and symptoms like seizures and he...
26 Feb 17min
General neurologists guide for diagnosis of atypical parkinsonian disorders
This consensus statement provides a practical diagnostic framework to help general neurologists identify atypical parkinsonian disorders (APDs), such as progressive supranuclear palsy and multiple sys...
25 Feb 15min
Refractory, intensive care–dependent NMDAR encephalitis
This research study establishes a formal definition for refractory, intensive care–dependent NMDAR encephalitis (RI-NMDARE), identifying it as cases requiring over 90 days of ICU support despite secon...
24 Feb 19min
